Scientific Program
The Group’s scientific program includes all phases of clinical research (phases 1 to 4). It also covers all types and subtypes of breast cancer: Hormone-receptor-positive – estrogen or progesterone (HR +); HER2 protein overexpression (HER2 +); Triple-negative, which does not involve hormone receptors nor those of the HER2 protein (HR- / HER2-); Genetic mutation (somatic / spontaneous or hereditary / transmitted), as well as all stages of the disease or extent of cancer, from in situ and early stages to metastatic cancer.
| Cancer Subtype | Time of treatment | Treatment Types |
|---|---|---|
| HR+/HER2- | Neoadjuvant | Chemotherapy |
| HR-/HER2+ | Adjuvant | Hormonal therapy |
| HR-/HER2- (mutated or not) | Post-Neoadjuvant | Immunotherapy |
| HR+/HER2+ | Prevention | |
| Genetic Mutations | Radiation therapy | |
| Supportive therapy | ||
| Surgery | ||
| Targeted therapy |
Clinical Trials Performed Within the Group
The consortium is presently involved in 30 or so clinical trials and is considering new ones regularly. Please refer to the table below to see what trials are ongoing at the Group’s hospitals.
How to use this table:
– Use the arrows to sort the columns in alphabetical order (in particular to sort the studies by status)
– Use the Search field with any keyword (hospital centre, cancer subtype etc.)
| Cancer Subtype | Study Name | Sponsor | Participating Hospitals | Status |
|---|---|---|---|---|
| HR+ & HER2- | TROPICS-02 (IMMU132-09) Phase 3 Study of Sacituzumab Govitecan vs Physician's Choice in Subjects With Hormonal Receptor-Positive Human Epidermal Growth Factor Receptor 2 Negative Metastatic Breast Cancer Who Have Failed at Least 2 Prior Chemotherapy Regimens (TROPICS-02) | Immunomedics Inc. | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DE L'ESTRIE – CHUS | Closed to recruitment |
| HR+ & HER2- | NSABP-B58 / MonarchE Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer | Eli Lilly in collaboration with NSABP Foundation Inc. | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DE L'ESTRIE – CHUS CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CHU DE QUEBEC – UNIVERSITE LAVAL | Closed to recruitment |
| HR+ & HER2- | NeaOnQ A prospective clinical utility and economic impact study of the Oncotype DX® Recurrence Score in in node-positive patients and in candidates for neoadjuvant therapy in Quebec | CHUM in collaboration with Genomic Health | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CHU DE QUEBEC – UNIVERSITE LAVAL MCGILL UNIVERSITY HEALTH CENTER (MUHC) | Closed to recruitment |
| HR+ & HER2- | CONTESSA (ODO-TE-B301) Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane | Odonate Therapeutics, Inc. | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT CIUSSS DE L'ESTRIE – CHUS CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL / JEWISH GENERAL HOSPITAL CHU DE QUEBEC – UNIVERSITE LAVAL MCGILL UNIVERSITY HEALTH CENTER (MUHC) | Closed to recruitment |
| ER+ & HER2- | EMERALD (RAD1901-308) Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial (EMERALD) | Radius Pharmaceuticals, Inc. | CHU DE QUEBEC – UNIVERSITE LAVAL CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) MCGILL UNIVERSITY HEALTH CENTER (MUHC) | Closed to recruitment |
| ER+ & HER2- | CheckMate 7FL (CA209-7FL) Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer (CheckMate 7FL) | Bristol-Myers Squibb | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DE L'ESTRIE – CHUS CIUSSS DE L’OUEST-DE-L’ÎLE-DE-MONTRÉAL/ ST. MARY'S HOSPITAL | Closed to recruitment |
| ER+ & HER2- | KEYNOTE-756 Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2–) Breast Cancer | Merck Sharp & Dohme Corp. | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL / JEWISH GENERAL HOSPITAL CHU DE QUEBEC – UNIVERSITE LAVAL CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT | In recruitment |
| ER+ & HER2- | NSABP-FB13 Assessment of the Biological and Clinical Effects of Palbociclib (PD 0332991) with Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Patients with Premenopausal Estrogen-Receptor Positive/HER2-Negative Primary Breast Cancer | NSABP Foundation Inc. | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL MCGILL UNIVERSITY HEALTH CENTER (MUHC) CHU DE QUEBEC – UNIVERSITE LAVAL CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT | Closed to recruitment |
| HR+ & HER2- | NATALEE (TRIO033) Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer | Novartis Pharmaceuticals in collaboration with Translational Research in Oncology | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL MCGILL UNIVERSITY HEALTH CENTER (MUHC) CHU DE QUEBEC – UNIVERSITE LAVAL CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT CIUSSS DE L'ESTRIE – CHUS | Closed to recruitment |
| HR+ & HER2- | XENERA Multi-center, double-blind, placebo-controlled, randomised phase II trial to compare the efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in post-menopausal women in post-menopausal women with Hormone Receptor Positive (HR+) and HER2- negative metastatic breast cancer and non-visceral disease | Boehringer Ingelheim | MCGILL UNIVERSITY HEALTH CENTER (MUHC) CHU DE QUEBEC – UNIVERSITE LAVAL | Closed to recruitment |
| HER2- & BRCA1/2 | LUCY Lynparza Breast Cancer Real-World Utility, Clinical Effectiveness and Safety Study - A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Monotherapy in the Treatment of HER2-ve Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutations | Astra Zeneca in collaboration with Parexel | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CHU DE QUEBEC – UNIVERSITE LAVAL | Closed to recruitment |
| HR- & HER2- (Triple negative) | NSABP-B59 Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo | NSABP Foundation Inc in collaboration with Genentech Inc. | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL MCGILL UNIVERSITY HEALTH CENTER (CUSM) CHU DE QUEBEC – UNIVERSITE LAVAL CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT | Closed to recruitment |
| HR- & HER2- (Triple negative) | ATTAIN Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine | Nektar Therapeutics | MCGILL UNIVERSITY HEALTH CENTER (MUHC) | Closed to recruitment |
| HR+ & HER2- / ER- & HER2- / HER2+ | TRIO-030 Pre-surgical Tissue-Acquisition Study to Evaluate Molecular Alterations in Human Breast Cancer Tissue Following Short-Term Exposure to the Androgen Receptor Antagonist ODM-20 | Translational Research in Oncology (TRIO) | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CHU DE QUEBEC – UNIVERSITE LAVAL CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL MCGILL UNIVERSITY HEALTH CENTER (MUHC) CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT | Closed to recruitment |
| HR+ & HER2- | CONTESSA 2 Multinational, Multicenter, Phase 2 Study of Tesetaxel Plus a Reduced Dose of Capecitabine in Patients With HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane | Odonate Therapeutics Inc. | ENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CHU DE QUEBEC – UNIVERSITE LAVAL MCGILL UNIVERSITY HEALTH CENTER (MUHC) CIUSSS DE L'ESTRIE – CHUS | Closed to recruitment |
| HR- & HER2- (Triple negative) / HER2- | CONTESSA-TRIO Multicenter, Phase 2 Study of Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Metastatic TNBC and Tesetaxel Monotherapy in Elderly Patients With HER2 Negative MBC | Odonate Therapeutics Inc. | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL MCGILL UNIVERSITY HEALTH CENTER (MUHC) CIUSSS DE L'ESTRIE – CENTRE HOSP. UNIV. DE SHERBROOKE | Closed to recruitment |
| HR- & HER2- (Triple negative) / HER2- | MK-7339-009 (KEYLYNK-009) Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) | Merck | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) MCGILL UNIVERSITY HEALTH CENTER (MUHC) | Closed to recruitment |
| HR+ & HER2- | KEYNOTE-B49 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor2-Negative (HR+/HER2-) Metastatic Breast Cancer (KEYNOTE-B49) | Merck | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CHU DE QUEBEC – UNIVERSITE LAVAL | In recruitment |
| HR+ & HER2- | LA LEAST Luminal A, Limited Endocrine Adjuvant Systemic Therapy. A phase II trial of abbreviated hormone therapy for low risk hormone receptor positive, HER2- early breast cancer. | BC Cancer Agency - Canadian Breast Cancer Foundation (CCSRI) | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CHU DE QUEBEC – UNIVERSITE LAVAL CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT CIUSSS DE L'ESTRIE – CHUS CISSS MONTÉRÉGIE-CENTRE / HÔPITAL CHARLES-LE MOYNE CIUSSS SAGUENAY-LAC-ST-JEAN / HÔPITAL DE CHICOUTIMI | In recruitment |
| ER+&HER2- | BO41843 A phase III randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of GDC-9545 combined with Palbociclib compared with Letrozole combined with Palbociclib in patients with Estrogen Receptor-Positive, HER2-Negative locally advanced or Metastatic Breast Cancer | Hoffmann-LaRoche | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CHU DE QUEBEC – UNIVERSITE LAVAL CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) MCGILL UNIVERSITY HEALTH CENTER (MUHC) CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT CIUSSS DE L'ESTRIE – CHUS | In recruitment |
| HER2+ | HER2CLIMB-02 A Randomized, Double-Blind, Phase 3 Study of Tucatinib or Placebo in Combination with Ado-Trastuzumab Emtansine (T-DM1) for Subjects with Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer | Seattle Genetics | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CHU DE QUEBEC – UNIVERSITE LAVAL CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) | Closed to recruitment |
| HER2+ | DESTINY-Breast05/NSABP-B60 A global Phase 3, randomized, open-label, study comparing T-DXd to T-DM1 in high-risk HER2+ early breast cancer patients with residual invasive disease following neoadjuvant therapy | Daiichi Sankyo & NSABP Foundation | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CHU DE QUEBEC – UNIVERSITE LAVAL CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) MCGILL UNIVERSITY HEALTH CENTER (MUHC) CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT | In recruitment |
| HER2+ | KATE-3 A randomized, multicenter, doubleblind, placebo-controlled phase III study of the efficacy and safety of trastuzumab emtansine in combination with atezolizumab or placebo in patients with HER2-positive and PD-L1-positive locally advanced or metastatic breast cancer who have received prior trastuzumab- (+/-pertuzumab) and taxane-based therapy (KATE3) | F. Hoffmann-La Roche Ltd | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) MCGILL UNIVERSITY HEALTH CENTER (MUHC) CIUSSS DE L'ESTRIE – CHUS | In recruitment |
| ER+& HER2- | SERD-15935 A randomized, multicenter, double-blind phase 3 study of SAR439859 plus palbociclib versus letrozole plus palbociclib for the treatment of premenopausal and postmenopausal women with ER (+), HER2 (-) breast cancer who have not received any prior systemic anticancer treatment for advanced disease | Sanofi | MCGILL UNIVERSITY HEALTH CENTER (MUHC) CIUSSS DE L'OUEST-DE-L'ILE-DE-MONTREAL/ ST. MARY'S HOSPITAL CISSS MONTÉRÉGIE-CENTRE / HÔPITAL CHARLES-LE MOYNE CIUSSS SAGUENAY-LAC-ST-JEAN / HÔPITAL DE CHICOUTIMI | In recruitment |
| HR+& HER2- | CAPITELLO-291 Phase III, double-blind, randomised study assessing the efficacy of capivasertib + fulvestrant vs placebo + fulvestrant for the treatment of patients with locally advanced (inoperable) or metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) breast cancer following recurrence or progression on or after aromatase inhibitor (AI) therapy | AstraZeneca | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) MCGILL UNIVERSITY HEALTH CENTER (MUHC) | In recruitment |
| HR+& HER2- | DESTINY-Breast-06 A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator’s Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting | AstraZeneca | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL MCGILL UNIVERSITY HEALTH CENTER (MUHC) CIUSSS DE L'ESTRIE – CHUS | In recruitment |
| HER2+ | DESTINY-Breast-07 A Phase 1b/2 Multicenter, Open-label, Dose Expansion Study to Explore the Safety, Tolerability, and Anti-tumor Activity of Trastuzumab Deruxtecan (DS 8201a, T-DXd) Monotherapy and Combination in Patients with Metastatic HER2-positive Breast Cancer - DESTINY-Breast07) | AstraZeneca | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL / HOPITAL GENERAL JUIF CHU DE QUEBEC – UNIVERSITE LAVAL | In recruitment |
| HER2+ | DESTINY-Breast09 Phase III, double-blind, randomised study assessing the efficacy of capivasertib + fulvestrant vs placebo + fulvestrant for the treatment of patients with locally advanced (inoperable) or metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) breast cancer following recurrence or progression on or after aromatase inhibitor (AI) therapy | AstraZeneca | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) MCGILL UNIVERSITY HEALTH CENTER (MUHC) CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HÔPITAL MAISONNEUVE-ROSEMONT CIUSSS DE L'OUEST-DE-L'ILE-DE-MONTREAL/ ST. MARY'S HOSPITAL | In recruitment |
| HER2+ | DESTINY-Breast-11 A phase III trial of neoadjuvant Trastuzumab Deruxtecan monotherapy or Trastuzumab Deruxtecan in sequence with paclitaxel + trastuzumab + pertuzumab vs doxorubicin + cyclophosphamide followed by paclitaxel + trastuzumab + pertuzumab in HER2-positive early breast cancer (Destiny-11) | AstraZeneca | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL MCGILL UNIVERSITY HEALTH CENTER (MUHC) CHU DE QUEBEC – UNIVERSITE LAVAL CIUSSS DE L'ESTRIE - CHUS | In preparation |
| HR+/HER2- | SERENA-6 A phase 3, double-bliind, randomized study to assess the efficacy and safety of switching to AZD9833 (an oral SERD) + CDK4/6 inhibitors (palbociclib or abemaciclib) vs continuing aromatase inhibitor + CDK4/6 inhibitors in patients with acquired ESR1 mutation without radiological progression during 1L treatment with AI + CDK4/6i for ER+/HER2- mBC-ctDNA guided early switch study | AstraZeneca | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CHU DE QUEBEC – UNIVERSITE LAVAL CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT | In recruitment |
| HR+/HER2- | SERENA-4 A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) Plus Palbociclib Versus Anastrozole Plus Palbociclib for the Treatment of Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease | AstraZeneca | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL | In recruitment |
| HR+/HER2- | TROPION-Breast-01 A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy | AstraZeneca | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CHU DE QUEBEC – UNIVERSITE LAVAL MCGILL UNIVERSITY HEALTH CENTRE (MUHC) | In recruitment |
| HR+/HER2- | CAPItello-292 A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) Plus Palbociclib Versus Anastrozole Plus Palbociclib for the Treatment of Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease | AstraZeneca | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CIUSSS DE L'ESTRIE - CHUS CIUSSS SAGUENAY-LAC-ST-JEAN / HÔPITAL DE CHICOUTIMI | In recruitment |
| ER+/HER2- | lidERA A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant GDC‑9545 compared with physician's choice of Adjuvant Endocrine Monotherapy In Patients With Estrogen Receptor−Positive, HER2‑Negative Early Breast Cancer | Genentech /TRIO/NSABP | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CHU DE QUEBEC – UNIVERSITE LAVAL CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) MCGILL UNVERSITY HEALTH CENTRE (MUHC) CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT CIUSSS DE L'ESTRIE - CHUS CIUSSS DU SAGUENAY-LAC-SAINT-JEAN / HÔPITAL DE CHICOUTIMI CISSS MONTÉRÉGIE-CENTRE / HÔPITAL CHARLES-LEMOYNE | In recruitment |
| CONCORDANCE Concordance between Liquid and Tissue Biopsy in Newly Diagnosed Metastatic Breast Cancer | London Health Sciences Centre (Dr. Ana Lohmann) | CHU DE QUEBEC – UNIVERSITE LAVAL CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) MCGILL UNIVERSITY HEALTH CENTER (MUHC) CIUSSS DU SAGUENAU-LAC-SAINT-JEAN / HÔPITAL DE CHICOUTIMI CISSS MONTÉRÉGIE-CENTRE / HÔPITAL CHARLES-LEMOYNE | In recruitment | |
| HER2+ | HER2CLIMB-05 A Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab for advanced HER2+ breast cancer | Seagen | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DU SAGUENAY-LAC-SAINT-JEAN / HÔPITAL DE CHICOUTIMI | In preparation |
| HER2+ | EPIK-B2 A Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab for advanced HER2+ breast cancer | Novartis | CHU DE QUEBEC – UNIVERSITE LAVAL | In preparation |
| Cancer Subtype | Study Name | Sponsor | Participating Hospitals | Status |
|---|---|---|---|---|
| HR+ & HER2- | TROPICS-02 (IMMU132-09) Phase 3 Study of Sacituzumab Govitecan vs Physician's Choice in Subjects With Hormonal Receptor-Positive Human Epidermal Growth Factor Receptor 2 Negative Metastatic Breast Cancer Who Have Failed at Least 2 Prior Chemotherapy Regimens (TROPICS-02) | Immunomedics Inc. | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DE L'ESTRIE – CHUS | Closed to recruitment |
| HR+ & HER2- | NSABP-B58 / MonarchE Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer | Eli Lilly in collaboration with NSABP Foundation Inc. | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DE L'ESTRIE – CHUS CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CHU DE QUEBEC – UNIVERSITE LAVAL | Closed to recruitment |
| HR+ & HER2- | NeaOnQ A prospective clinical utility and economic impact study of the Oncotype DX® Recurrence Score in in node-positive patients and in candidates for neoadjuvant therapy in Quebec | CHUM in collaboration with Genomic Health | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CHU DE QUEBEC – UNIVERSITE LAVAL MCGILL UNIVERSITY HEALTH CENTER (MUHC) | Closed to recruitment |
| HR+ & HER2- | CONTESSA (ODO-TE-B301) Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane | Odonate Therapeutics, Inc. | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT CIUSSS DE L'ESTRIE – CHUS CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL / JEWISH GENERAL HOSPITAL CHU DE QUEBEC – UNIVERSITE LAVAL MCGILL UNIVERSITY HEALTH CENTER (MUHC) | Closed to recruitment |
| ER+ & HER2- | EMERALD (RAD1901-308) Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial (EMERALD) | Radius Pharmaceuticals, Inc. | CHU DE QUEBEC – UNIVERSITE LAVAL CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) MCGILL UNIVERSITY HEALTH CENTER (MUHC) | Closed to recruitment |
| ER+ & HER2- | CheckMate 7FL (CA209-7FL) Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer (CheckMate 7FL) | Bristol-Myers Squibb | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DE L'ESTRIE – CHUS CIUSSS DE L’OUEST-DE-L’ÎLE-DE-MONTRÉAL/ ST. MARY'S HOSPITAL | Closed to recruitment |
| ER+ & HER2- | KEYNOTE-756 Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2–) Breast Cancer | Merck Sharp & Dohme Corp. | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL / JEWISH GENERAL HOSPITAL CHU DE QUEBEC – UNIVERSITE LAVAL CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT | In recruitment |
| ER+ & HER2- | NSABP-FB13 Assessment of the Biological and Clinical Effects of Palbociclib (PD 0332991) with Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Patients with Premenopausal Estrogen-Receptor Positive/HER2-Negative Primary Breast Cancer | NSABP Foundation Inc. | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL MCGILL UNIVERSITY HEALTH CENTER (MUHC) CHU DE QUEBEC – UNIVERSITE LAVAL CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT | Closed to recruitment |
| HR+ & HER2- | NATALEE (TRIO033) Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer | Novartis Pharmaceuticals in collaboration with Translational Research in Oncology | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL MCGILL UNIVERSITY HEALTH CENTER (MUHC) CHU DE QUEBEC – UNIVERSITE LAVAL CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT CIUSSS DE L'ESTRIE – CHUS | Closed to recruitment |
| HR+ & HER2- | XENERA Multi-center, double-blind, placebo-controlled, randomised phase II trial to compare the efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in post-menopausal women in post-menopausal women with Hormone Receptor Positive (HR+) and HER2- negative metastatic breast cancer and non-visceral disease | Boehringer Ingelheim | MCGILL UNIVERSITY HEALTH CENTER (MUHC) CHU DE QUEBEC – UNIVERSITE LAVAL | Closed to recruitment |
| HER2- & BRCA1/2 | LUCY Lynparza Breast Cancer Real-World Utility, Clinical Effectiveness and Safety Study - A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Monotherapy in the Treatment of HER2-ve Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutations | Astra Zeneca in collaboration with Parexel | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CHU DE QUEBEC – UNIVERSITE LAVAL | Closed to recruitment |
| HR- & HER2- (Triple negative) | NSABP-B59 Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo | NSABP Foundation Inc in collaboration with Genentech Inc. | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL MCGILL UNIVERSITY HEALTH CENTER (CUSM) CHU DE QUEBEC – UNIVERSITE LAVAL CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT | Closed to recruitment |
| HR- & HER2- (Triple negative) | ATTAIN Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine | Nektar Therapeutics | MCGILL UNIVERSITY HEALTH CENTER (MUHC) | Closed to recruitment |
| HR+ & HER2- / ER- & HER2- / HER2+ | TRIO-030 Pre-surgical Tissue-Acquisition Study to Evaluate Molecular Alterations in Human Breast Cancer Tissue Following Short-Term Exposure to the Androgen Receptor Antagonist ODM-20 | Translational Research in Oncology (TRIO) | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CHU DE QUEBEC – UNIVERSITE LAVAL CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL MCGILL UNIVERSITY HEALTH CENTER (MUHC) CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT | Closed to recruitment |
| HR+ & HER2- | CONTESSA 2 Multinational, Multicenter, Phase 2 Study of Tesetaxel Plus a Reduced Dose of Capecitabine in Patients With HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane | Odonate Therapeutics Inc. | ENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CHU DE QUEBEC – UNIVERSITE LAVAL MCGILL UNIVERSITY HEALTH CENTER (MUHC) CIUSSS DE L'ESTRIE – CHUS | Closed to recruitment |
| HR- & HER2- (Triple negative) / HER2- | CONTESSA-TRIO Multicenter, Phase 2 Study of Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Metastatic TNBC and Tesetaxel Monotherapy in Elderly Patients With HER2 Negative MBC | Odonate Therapeutics Inc. | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL MCGILL UNIVERSITY HEALTH CENTER (MUHC) CIUSSS DE L'ESTRIE – CENTRE HOSP. UNIV. DE SHERBROOKE | Closed to recruitment |
| HR- & HER2- (Triple negative) / HER2- | MK-7339-009 (KEYLYNK-009) Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) | Merck | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) MCGILL UNIVERSITY HEALTH CENTER (MUHC) | Closed to recruitment |
| HR+ & HER2- | KEYNOTE-B49 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor2-Negative (HR+/HER2-) Metastatic Breast Cancer (KEYNOTE-B49) | Merck | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CHU DE QUEBEC – UNIVERSITE LAVAL | In recruitment |
| HR+ & HER2- | LA LEAST Luminal A, Limited Endocrine Adjuvant Systemic Therapy. A phase II trial of abbreviated hormone therapy for low risk hormone receptor positive, HER2- early breast cancer. | BC Cancer Agency - Canadian Breast Cancer Foundation (CCSRI) | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CHU DE QUEBEC – UNIVERSITE LAVAL CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT CIUSSS DE L'ESTRIE – CHUS CISSS MONTÉRÉGIE-CENTRE / HÔPITAL CHARLES-LE MOYNE CIUSSS SAGUENAY-LAC-ST-JEAN / HÔPITAL DE CHICOUTIMI | In recruitment |
| ER+&HER2- | BO41843 A phase III randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of GDC-9545 combined with Palbociclib compared with Letrozole combined with Palbociclib in patients with Estrogen Receptor-Positive, HER2-Negative locally advanced or Metastatic Breast Cancer | Hoffmann-LaRoche | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CHU DE QUEBEC – UNIVERSITE LAVAL CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) MCGILL UNIVERSITY HEALTH CENTER (MUHC) CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT CIUSSS DE L'ESTRIE – CHUS | In recruitment |
| HER2+ | HER2CLIMB-02 A Randomized, Double-Blind, Phase 3 Study of Tucatinib or Placebo in Combination with Ado-Trastuzumab Emtansine (T-DM1) for Subjects with Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer | Seattle Genetics | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CHU DE QUEBEC – UNIVERSITE LAVAL CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) | Closed to recruitment |
| HER2+ | DESTINY-Breast05/NSABP-B60 A global Phase 3, randomized, open-label, study comparing T-DXd to T-DM1 in high-risk HER2+ early breast cancer patients with residual invasive disease following neoadjuvant therapy | Daiichi Sankyo & NSABP Foundation | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CHU DE QUEBEC – UNIVERSITE LAVAL CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) MCGILL UNIVERSITY HEALTH CENTER (MUHC) CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT | In recruitment |
| HER2+ | KATE-3 A randomized, multicenter, doubleblind, placebo-controlled phase III study of the efficacy and safety of trastuzumab emtansine in combination with atezolizumab or placebo in patients with HER2-positive and PD-L1-positive locally advanced or metastatic breast cancer who have received prior trastuzumab- (+/-pertuzumab) and taxane-based therapy (KATE3) | F. Hoffmann-La Roche Ltd | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) MCGILL UNIVERSITY HEALTH CENTER (MUHC) CIUSSS DE L'ESTRIE – CHUS | In recruitment |
| ER+& HER2- | SERD-15935 A randomized, multicenter, double-blind phase 3 study of SAR439859 plus palbociclib versus letrozole plus palbociclib for the treatment of premenopausal and postmenopausal women with ER (+), HER2 (-) breast cancer who have not received any prior systemic anticancer treatment for advanced disease | Sanofi | MCGILL UNIVERSITY HEALTH CENTER (MUHC) CIUSSS DE L'OUEST-DE-L'ILE-DE-MONTREAL/ ST. MARY'S HOSPITAL CISSS MONTÉRÉGIE-CENTRE / HÔPITAL CHARLES-LE MOYNE CIUSSS SAGUENAY-LAC-ST-JEAN / HÔPITAL DE CHICOUTIMI | In recruitment |
| HR+& HER2- | CAPITELLO-291 Phase III, double-blind, randomised study assessing the efficacy of capivasertib + fulvestrant vs placebo + fulvestrant for the treatment of patients with locally advanced (inoperable) or metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) breast cancer following recurrence or progression on or after aromatase inhibitor (AI) therapy | AstraZeneca | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) MCGILL UNIVERSITY HEALTH CENTER (MUHC) | In recruitment |
| HR+& HER2- | DESTINY-Breast-06 A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator’s Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting | AstraZeneca | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL MCGILL UNIVERSITY HEALTH CENTER (MUHC) CIUSSS DE L'ESTRIE – CHUS | In recruitment |
| HER2+ | DESTINY-Breast-07 A Phase 1b/2 Multicenter, Open-label, Dose Expansion Study to Explore the Safety, Tolerability, and Anti-tumor Activity of Trastuzumab Deruxtecan (DS 8201a, T-DXd) Monotherapy and Combination in Patients with Metastatic HER2-positive Breast Cancer - DESTINY-Breast07) | AstraZeneca | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL / HOPITAL GENERAL JUIF CHU DE QUEBEC – UNIVERSITE LAVAL | In recruitment |
| HER2+ | DESTINY-Breast09 Phase III, double-blind, randomised study assessing the efficacy of capivasertib + fulvestrant vs placebo + fulvestrant for the treatment of patients with locally advanced (inoperable) or metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) breast cancer following recurrence or progression on or after aromatase inhibitor (AI) therapy | AstraZeneca | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) MCGILL UNIVERSITY HEALTH CENTER (MUHC) CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HÔPITAL MAISONNEUVE-ROSEMONT CIUSSS DE L'OUEST-DE-L'ILE-DE-MONTREAL/ ST. MARY'S HOSPITAL | In recruitment |
| HER2+ | DESTINY-Breast-11 A phase III trial of neoadjuvant Trastuzumab Deruxtecan monotherapy or Trastuzumab Deruxtecan in sequence with paclitaxel + trastuzumab + pertuzumab vs doxorubicin + cyclophosphamide followed by paclitaxel + trastuzumab + pertuzumab in HER2-positive early breast cancer (Destiny-11) | AstraZeneca | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL MCGILL UNIVERSITY HEALTH CENTER (MUHC) CHU DE QUEBEC – UNIVERSITE LAVAL CIUSSS DE L'ESTRIE - CHUS | In preparation |
| HR+/HER2- | SERENA-6 A phase 3, double-bliind, randomized study to assess the efficacy and safety of switching to AZD9833 (an oral SERD) + CDK4/6 inhibitors (palbociclib or abemaciclib) vs continuing aromatase inhibitor + CDK4/6 inhibitors in patients with acquired ESR1 mutation without radiological progression during 1L treatment with AI + CDK4/6i for ER+/HER2- mBC-ctDNA guided early switch study | AstraZeneca | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CHU DE QUEBEC – UNIVERSITE LAVAL CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT | In recruitment |
| HR+/HER2- | SERENA-4 A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) Plus Palbociclib Versus Anastrozole Plus Palbociclib for the Treatment of Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease | AstraZeneca | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL | In recruitment |
| HR+/HER2- | TROPION-Breast-01 A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy | AstraZeneca | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CHU DE QUEBEC – UNIVERSITE LAVAL MCGILL UNIVERSITY HEALTH CENTRE (MUHC) | In recruitment |
| HR+/HER2- | CAPItello-292 A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) Plus Palbociclib Versus Anastrozole Plus Palbociclib for the Treatment of Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease | AstraZeneca | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CIUSSS DE L'ESTRIE - CHUS CIUSSS SAGUENAY-LAC-ST-JEAN / HÔPITAL DE CHICOUTIMI | In recruitment |
| ER+/HER2- | lidERA A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant GDC‑9545 compared with physician's choice of Adjuvant Endocrine Monotherapy In Patients With Estrogen Receptor−Positive, HER2‑Negative Early Breast Cancer | Genentech /TRIO/NSABP | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CHU DE QUEBEC – UNIVERSITE LAVAL CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) MCGILL UNVERSITY HEALTH CENTRE (MUHC) CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT CIUSSS DE L'ESTRIE - CHUS CIUSSS DU SAGUENAY-LAC-SAINT-JEAN / HÔPITAL DE CHICOUTIMI CISSS MONTÉRÉGIE-CENTRE / HÔPITAL CHARLES-LEMOYNE | In recruitment |
| CONCORDANCE Concordance between Liquid and Tissue Biopsy in Newly Diagnosed Metastatic Breast Cancer | London Health Sciences Centre (Dr. Ana Lohmann) | CHU DE QUEBEC – UNIVERSITE LAVAL CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) MCGILL UNIVERSITY HEALTH CENTER (MUHC) CIUSSS DU SAGUENAU-LAC-SAINT-JEAN / HÔPITAL DE CHICOUTIMI CISSS MONTÉRÉGIE-CENTRE / HÔPITAL CHARLES-LEMOYNE | In recruitment | |
| HER2+ | HER2CLIMB-05 A Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab for advanced HER2+ breast cancer | Seagen | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DU SAGUENAY-LAC-SAINT-JEAN / HÔPITAL DE CHICOUTIMI | In preparation |
| HER2+ | EPIK-B2 A Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab for advanced HER2+ breast cancer | Novartis | CHU DE QUEBEC – UNIVERSITE LAVAL | In preparation |